Novo Nordisk Partners with OpenAI to Integrate AI Across Drug Discovery, Manufacturing, and Operations

CNBC·medium signal

Novo Nordisk announced a strategic partnership with OpenAI on April 14 to deploy AI across its entire pipeline — from drug discovery and clinical trials to manufacturing, supply chains, and commercial operations. Pilot programs launch immediately with full integration planned by end of 2026. The Danish pharma giant is locked in a race with Eli Lilly for weight-loss market dominance and is using the partnership to accelerate next-generation drugs beyond its Wegovy franchise. OpenAI will also assist in upskilling Novo's global workforce. Covered by CNBC, Bloomberg, and Euronews.